SCHEMBL3142287

SCHEMBL3142287

CCC(Nc1cccc(O)c1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
TSHR P16473 1/20 0.49
MAPT P10636 5/20 0.44
NLRP3 Q96P20 6/20 0.43
KMT2A Q03164 4/20 0.43
MAPK1 P28482 4/20 0.43
MEN1 O00255 3/20 0.43
HSD17B10 Q99714 3/20 0.43
ALOX15 P16050 2/20 0.43
USP2 O75604 1/20 0.43
APP P05067 1/20 0.43
HSP90AA1 P07900 1/20 0.43
HSP90AB1 P08238 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
ALOX12 P18054 1/20 0.43
CYP2C19 P33261 1/20 0.43
SNCA P37840 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1274521 0.84 ITGB3 (0.53) ALDH1A1CYP1A2CYP3A4TSHRMAPT
SCHEMBL11478495 0.83 SIRT2 (0.50) ALDH1A1CYP1A2CYP3A4TSHRNLRP3
SCHEMBL2878630 0.83 ALDH1A1 (0.50) ALDH1A1CYP3A4TSHRMAPTKMT2A
SCHEMBL4526295 0.83 ALDH1A1 (0.50) ALDH1A1CYP3A4TSHRMAPTKMT2A
SCHEMBL8635820 0.83 ALDH1A1 (0.50) ALDH1A1CYP3A4TSHRMAPTKMT2A
SCHEMBL1531484 0.83 MAPK1 (0.56) ALDH1A1MAPTKMT2AMAPK1MEN1
SCHEMBL1531481 0.83 MAPK1 (0.56) ALDH1A1MAPTKMT2AMAPK1MEN1
SCHEMBL2283372 0.79 GAA (0.42) ALDH1A1CYP1A2CYP3A4TSHRMAPT
SCHEMBL5328091 0.78 CYP3A4 (0.53) ALDH1A1CYP1A2CYP3A4TSHRMAPT
SCHEMBL5328095 0.78 CYP3A4 (0.53) ALDH1A1CYP1A2CYP3A4TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236826-B2 Diarylether derivatives as antitumor agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-08-07 US disclosed
US-8188277-B2 Aromatic compounds for suppressing the generation of collagen OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-05-29 US disclosed
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-01-07 US disclosed
US-20070270422-A1 Aromatic Compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS ROS1, CBR1, CBR3 ALDH1A1 265/4885CYP1A2 979/4885CYP3A4 910/4885
US-20070270422-A1 Aromatic Compounds COL1A1, COL2A1, COL14A1 ALDH1A1 475/4885CYP1A2 100/4885CYP3A4 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.